Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Flexible Dose Study on the Efficacy of Lu AA21004 on Cognitive Dysfunction in Adult Subjects With Major Depressive Disorder (MDD).

Trial Profile

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Flexible Dose Study on the Efficacy of Lu AA21004 on Cognitive Dysfunction in Adult Subjects With Major Depressive Disorder (MDD).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vortioxetine (Primary) ; Duloxetine
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms CONNECT
  • Sponsors Takeda
  • Most Recent Events

    • 02 May 2018 According to a Takeda Pharma media release, the US FDA has approved a supplemental new drug application for vortioxetine to include new data from the FOCUS and CONNECT studies in the labelling.
    • 12 Mar 2018 Results of post hoc subgroup analysis assessing effect of vortioxetine on functional capacity in demographic and clinical subgroups of patients with major depressive disorder published in the International Journal of Neuropsychopharmacology
    • 04 Feb 2016 According to Lundbeck media release, FDA Psychopharmacologic Drug Advisory Committee supports the effectiveness of Brintellix and reviewed data from this trial.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top